JW Therapeutics (02126) submitted its Monthly Return for the period ended 31 March 2026, confirming a stable capital structure and ongoing public-float compliance.

• Authorised capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, equivalent to authorised share capital of USD 50,000.

• Issued share capital was unchanged at 416.47 million shares, and the company continued to hold no treasury shares. The Exchange-required public float threshold of 25% was met.

• No shares were issued, cancelled, or repurchased during the month, and no proceeds were generated from option exercises.

• Share-based incentives: – Outstanding share options across Pre-IPO and Post-IPO schemes totalled 13.59 million units. – The Post-IPO Incentivization Scheme still allows for up to 13.71 million shares to be issued upon future grants and exercises. – Restricted Share Unit programmes carried 1.20 million shares available for potential issuance, with no activity recorded in March.

• The company reported no warrants, convertible securities, or other equity-linked instruments. All board and regulatory confirmations required under Hong Kong listing rules were provided.